BRAF and melanoma: Additionally, in the phase 3 clinical trial CheckMate 067, a 6.5-year follow-up analysis revealed that the combination treatment of nivolumab and ipilimumab worked better than nivolumab alone in patients with BRAF-mutant melanoma (6-year PFS 38% vs. 23% and 6.5-year overall survival (OS) of 57% vs. 43%) [48].